Blood Res.
2022 Mar;57(1):80-84. 10.5045/br.2021.2021198.
Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia
- Affiliations
-
- 1Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
- 2Seoul National University Cancer Research Institute, Seoul, Korea
- 3Wide River Institute of Immunology, Seoul National University, Seoul, Korea
- KMID: 2527502
- DOI: http://doi.org/10.5045/br.2021.2021198
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities
- A Case of Acute Promyelocytic Leukemia with Co-existence of BCR-ABL1 and PML-RARA Rearrangements Detected by PCR
- Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
- Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
- Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach
